Strides Arcolab has rallied 5% to Rs 487 after the pharmaceutical company announced that its Oral Dosage Forms manufacturing site (KRS Gardens) in Bangalore was recently inspected by the United States Food and Drug Administration (US FDA) as part of GMP compliance audit and the facility continues to be approved.
The last US FDA inspection and approval for this facility was in the year 2011, Strides Arcolab said in a statement.
The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets and capsules (both hard gelatine and soft gelatine). The manufacturing plant supports important current and future submissions for the US Market.
The stock opened at Rs 469 and hit a high of Rs 490 on the BSE. A combined around 430,000 shares already changed hands till 0945 hours as against an average sub 400,000 shares that were traded daily in past two weeks on the BSE and NSE.
The last US FDA inspection and approval for this facility was in the year 2011, Strides Arcolab said in a statement.
The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets and capsules (both hard gelatine and soft gelatine). The manufacturing plant supports important current and future submissions for the US Market.
The stock opened at Rs 469 and hit a high of Rs 490 on the BSE. A combined around 430,000 shares already changed hands till 0945 hours as against an average sub 400,000 shares that were traded daily in past two weeks on the BSE and NSE.